RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q4 2020
Top Holdings102 positions
ROCKET PHARMACEUTICALS INC | 17.1M | $935.6M | 15.7% | $18.09 | +209.82% | 8 qtrssince 2019-Q1 | Increased 63 |
IMMUNOVANT INC | 7.6M | $350.7M | 5.9% | $22.69 | +117.45% | 5 qtrssince 2019-Q4 | Increased 61 |
PTC THERAPEUTICS INC | 4.2M | $257.7M | 4.3% | $40.33 | +51.45% | 8 qtrssince 2019-Q1 | Increased 60 |
MIRATI THERAPEUTICS INC | 1.1M | $231.6M | 3.9% | — | — | 8 qtrssince 2019-Q1 | Decreased 0 |
STOKE THERAPEUTICS INC | 3.5M | $219.5M | 3.7% | $29.08 | +106.54% | 7 qtrssince 2019-Q2 | Unchanged 0 |
ALNYLAM PHARMACEUTICALS INC | 1.7M | $218.6M | 3.7% | $81.24 | +61.30% | 8 qtrssince 2019-Q1 | Unchanged 0 |
NATERA INC | 1.7M | $170.4M | 2.9% | $38.24 | +160.26% | 6 qtrssince 2019-Q3 | Increased 52 |
DICERNA PHARMACEUTICALS INC | 7.3M | $159.8M | 2.7% | — | — | 8 qtrssince 2019-Q1 | Increased 52 |
ARVINAS INC | 1.8M | $152.1M | 2.6% | $82.53 | 0.00% | 1 qtr | New 78 |
VERICEL CORP | 4.5M | $139.5M | 2.3% | $17.25 | +82.66% | 8 qtrssince 2019-Q1 | Increased 60 |
AXSOME THERAPEUTICS INC | 1.7M | $136.3M | 2.3% | $49.30 | +68.89% | 8 qtrssince 2019-Q1 | Increased 52 |
ILLUMINA INC | 361,778 | $133.9M | 2.2% | $326.60 | +8.44% | 2 qtrssince 2020-Q3 | Increased 84 |
CERNER CORP | 1.7M | $133.5M | 2.2% | — | — | 3 qtrssince 2020-Q2 | Increased 62 |
MASIMO CORP | 469,416 | $126M | 2.1% | $157.61 | +69.73% | 8 qtrssince 2019-Q1 | Increased 54 |
GLOBUS MED INC | 1.6M | $107M | 1.8% | $64.92 | 0.00% | 1 qtr | New 69 |
AVIDITY BIOSCIENCES INC | 4M | $102M | 1.7% | $27.04 | -1.63% | 3 qtrssince 2020-Q2 | Unchanged 0 |
TARSUS PHARMACEUTICALS INC | 2.5M | $99M | 1.7% | $41.92 | 0.00% | 1 qtr | New 68 |
AXONICS INC | 1.9M | $94M | 1.6% | — | — | 8 qtrssince 2019-Q1 | Unchanged 0 |
DERMTECH INC | 2.9M | $93.7M | 1.6% | — | — | 6 qtrssince 2019-Q3 | Unchanged 0 |
10X GENOMICS INC | 660,933 | $93.6M | 1.6% | $79.79 | +78.73% | 6 qtrssince 2019-Q3 | Unchanged 0 |
RTW INVESTMENTS, LP manages $6B across 102 positions as of Q4 2020. Top holdings: RCKT (15.7%), IMVT (5.9%), PTCT (4.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3.5/5.0.
Active quarter - 26 new positions, 14 exits, 35 increased. Top move: ILMN (INCREASED, conviction 84). Portfolio: $6.0B across 102 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR